Clinic Roundup

• Durata Therapeutics Inc., of Morristown, N.J., reached its target enrollment for DISCOVER 2 (Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response), the second global Phase III trial of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.